INNOVATION:  UCLA researchers have identified several compounds that target a particular pathway in the cell responsible for protection against ionizing radiation. The compounds act by upregulating the main effector protein of the pathway, thereby increasing the cell's ability to survive radiation. These compounds can be administered before or after radiation exposure. Currently, the compounds have been tested in vitro for their ability to increase the resistance of cultured cells to radiation. Animal studies are underway.

POTENTIAL APPLICATIONS 

• Treatment and prevention of the harmful effects of radiation

ADVANTAGES

• This invention provides compounds that should not have the side effects associated with Amifostine, the only FDA approved radioprotector.
• Some of the compounds have been FDA approved for other indications, therefore have a known safety profile.
• Targeting this particular cellular pathway should result in drugs that can be used for prophylaxis, mitigation and treatment of radiation.

Reference: UCLA Case No. 2007-406